A bioengineered tattoo monitors blood calc...Swiss researchers have created a biomedical tattoo that becomes visible on the skin of mice in response to elevated levels of calcium in the blood. more ➔
German biotech sector growingThe German biotech industry has shown tremendous growth in 2017. According to figures of BIOCOM, turnover, employees or number of start-ups – many key figures for 2017 exceeded those of the record year … more ➔
Servier to bag Shire’s cancer busine...French Servier boosts its cancer drug portfolio acquiring Shire plcs oncology pipeline, which earned about US$260m last year, for US$2.4bn in cash. more ➔
Germany to boost the bioeconomyShortly before the Global Bioeconomy Summit (19.-20.4.2018) in Berlin will begin, Germany’s new Research Minister Anja Karliczek announced three major initiatives to strengthen the biologisation of the … more ➔
Canopy acquires Czech Annabis Medical sro Canopy Growth Corp. is growing its medical cannabis business in Europe with the acquisition of Czech market leader Annabis Medical sro. more ➔
New Pierre Guerin site in Hildesheim, Germ...Mid last year, the company Pierre Guerin has opened a new location in Germany, Hildesheim. more ➔
GSK pass orphan gene therapy assets to Orc...British drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. … more ➔
Alexion in €639m bid for Wilson Therapeu...A public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics Board of Directors. Alexions SEK232/share bid would total in an acqusition price … more ➔
Novartis enters SMA race acquiring AveXis... Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis … more ➔
Blood test predincting Alzheimer’s p...A newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis. more ➔
